BRPI0813777B8 - composto, composição farmacêutica, e, uso de um composto - Google Patents
composto, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BRPI0813777B8 BRPI0813777B8 BRPI0813777A BRPI0813777A BRPI0813777B8 BR PI0813777 B8 BRPI0813777 B8 BR PI0813777B8 BR PI0813777 A BRPI0813777 A BR PI0813777A BR PI0813777 A BRPI0813777 A BR PI0813777A BR PI0813777 B8 BRPI0813777 B8 BR PI0813777B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- substituted
- oncological
- nociceptive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2007/002390 WO2008001076A1 (en) | 2006-06-26 | 2007-06-26 | Fused thiazole derivatives as kinase inhibitors |
GBPCT/GB2007/002390 | 2007-06-26 | ||
PCT/GB2008/002194 WO2009001089A1 (en) | 2007-06-26 | 2008-06-24 | Fused thiazole derivatives as kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0813777A2 BRPI0813777A2 (pt) | 2014-12-30 |
BRPI0813777B1 BRPI0813777B1 (pt) | 2020-12-08 |
BRPI0813777B8 true BRPI0813777B8 (pt) | 2021-05-25 |
Family
ID=39737000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0813777A BRPI0813777B8 (pt) | 2007-06-26 | 2008-06-24 | composto, composição farmacêutica, e, uso de um composto |
Country Status (8)
Country | Link |
---|---|
JP (1) | JP5570981B2 (pt) |
KR (1) | KR101577314B1 (pt) |
BR (1) | BRPI0813777B8 (pt) |
HK (1) | HK1140756A1 (pt) |
NZ (1) | NZ581919A (pt) |
SI (1) | SI2170906T1 (pt) |
UA (1) | UA99469C2 (pt) |
WO (1) | WO2009001089A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2638323T3 (es) * | 2009-05-20 | 2017-10-19 | Glaxosmithkline Llc | Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa |
EP2643327A1 (en) * | 2010-11-24 | 2013-10-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
WO2020056269A1 (en) * | 2018-09-13 | 2020-03-19 | Stemline Therapeutics, Inc. | Methods for treating centronuclear myopathy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0508471D0 (en) | 2005-04-26 | 2005-06-01 | Celltech R&D Ltd | Therapeutic agents |
-
2008
- 2008-06-24 BR BRPI0813777A patent/BRPI0813777B8/pt active IP Right Grant
- 2008-06-24 NZ NZ581919A patent/NZ581919A/en unknown
- 2008-06-24 WO PCT/GB2008/002194 patent/WO2009001089A1/en active Application Filing
- 2008-06-24 JP JP2010514106A patent/JP5570981B2/ja active Active
- 2008-06-24 KR KR1020107001844A patent/KR101577314B1/ko active IP Right Grant
- 2008-06-24 SI SI200830975T patent/SI2170906T1/sl unknown
- 2008-06-24 UA UAA201000774A patent/UA99469C2/ru unknown
-
2010
- 2010-07-23 HK HK10107097.5A patent/HK1140756A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SI2170906T1 (sl) | 2013-07-31 |
NZ581919A (en) | 2011-08-26 |
BRPI0813777A2 (pt) | 2014-12-30 |
HK1140756A1 (en) | 2010-10-22 |
KR20100040736A (ko) | 2010-04-20 |
WO2009001089A1 (en) | 2008-12-31 |
BRPI0813777B1 (pt) | 2020-12-08 |
KR101577314B1 (ko) | 2015-12-14 |
UA99469C2 (ru) | 2012-08-27 |
JP5570981B2 (ja) | 2014-08-13 |
JP2011504164A (ja) | 2011-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201000038A1 (ru) | Конденсированные производные тиазола в качестве ингибиторов киназ | |
ATE526021T1 (de) | Kondensierte thiazol-derivate als kinase-hemmer | |
NO20083739L (no) | Tieno-pyridinderivater som MEK-inhibitorer | |
NO20060279L (no) | Thienopyridonderivater som kinaseinhibitorer | |
BRPI0518169A (pt) | tiazolil-dihidro-indazóis | |
UY30183A1 (es) | Derivados de quinolina | |
CL2008002255A1 (es) | Compuesto 3-({4-(2,2-difluoroetil)-3-(1h-pirrolo [2,3-b] piridin-5-il)-1h-pirazol-4-il] pirimidin-2-il}amino)propanonitrilo, inhibidor de raf; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del crecimiento celular anormal o cualquier enfermedad o afeccion mediada por raf. | |
BRPI1006602A2 (pt) | composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição | |
NO20092657L (no) | Bicyclic heterocyclic compounds as FGFR inhibitors | |
ECSP088324A (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas | |
NO20092723L (no) | Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer | |
NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
CL2012001027A1 (es) | Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek. | |
CL2013000351A1 (es) | Compuestos derivados de 2-(arilamino)-3h-imidazo[4,5-b]piridina-6-carboxamida; inhibidores de la prostaglandina e2 sintasa-1 microsomal (mpges-1) composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias. | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
CO6541645A2 (es) | Compuestos de indol y su uso farmaceutico | |
CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
CL2008001303A1 (es) | Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer. | |
NO20091893L (no) | Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav. | |
WO2020041169A3 (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
NO20081133L (no) | Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer | |
BRPI0924617A8 (pt) | Compostos heterociclicos de fenoximetila | |
IN2015DN03751A (pt) | ||
NO20065073L (no) | Nye beta-agonister, metoder for deres fremstilling og deres anvendelse som medikamenter. | |
BRPI0813777B8 (pt) | composto, composição farmacêutica, e, uso de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |